Literature DB >> 18250424

Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques.

Ali Azizi1, David E Anderson, José V Torres, Andrei Ogrel, Masoud Ghorbani, Catalina Soare, Paul Sandstrom, Jocelyne Fournier, Francisco Diaz-Mitoma.   

Abstract

One of the major obstacles in the design of an effective vaccine against HIV-1 is its antigenic variation, which results in viral escape from the immune system. Through a bioinformatics approach, we developed an innovative multivalent HIV-1 vaccine comprised of a pool of 176 lipidated and nonlipidated peptides representing variable regions of Env and Gag proteins. The potency and breadth of the candidate vaccine against a panel of HIV-1 subtypes was evaluated in nonhuman primate (cynomolgus macaques) and humanized mouse (HLA-A2.1) models. The results demonstrate strong immunogenicity with both breadth (humoral and cellular immunity) and depth (immune recognition of widely divergent viral sequences) against heterologous HIV-1 subtypes A-F.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250424     DOI: 10.4049/jimmunol.180.4.2174

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

Review 2.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

Review 3.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

Review 4.  HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen.

Authors:  Sherri L Surman; Robert Sealy; Bart G Jones; Julia L Hurwitz
Journal:  Hum Vaccin       Date:  2009-04

Review 5.  Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Authors:  Robert Sealy; Karen S Slobod; Patricia Flynn; Kristen Branum; Sherri Surman; Bart Jones; Pamela Freiden; Timothy Lockey; Nanna Howlett; Julia L Hurwitz
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

6.  Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Authors:  Brian Burke; Victor Raúl Gómez-Román; Ying Lian; Yide Sun; Elaine Kan; Jeffrey Ulmer; Indresh K Srivastava; Susan W Barnett
Journal:  Virology       Date:  2009-02-27       Impact factor: 3.616

7.  Frequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs.

Authors:  Sinu Paul; Helen Piontkivska
Journal:  BMC Microbiol       Date:  2010-08-09       Impact factor: 3.605

8.  Characterization of a branched lipopeptide candidate vaccine against influenza A/Puerto Rico 8/34 which is recognized by human B and T-cell immune responses.

Authors:  Liz Samayoa; Francisco Diaz-Mitoma; Ali Azizi
Journal:  Virol J       Date:  2011-06-16       Impact factor: 4.099

Review 9.  Peptide Vaccine: Progress and Challenges.

Authors:  Weidang Li; Medha D Joshi; Smita Singhania; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Vaccines (Basel)       Date:  2014-07-02

10.  In silico CD4+, CD8+ T-cell and B-cell immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus.

Authors:  Essam Mohammed Janahi; Anupam Dhasmana; Vandana Srivastava; Aditya Narayan Sarangi; Sana Raza; Jamal M Arif; Madan Lal Bramha Bhatt; Mohtashim Lohani; Mohammed Yahya Areeshi; Anand Murari Saxena; Shafiul Haque
Journal:  EXCLI J       Date:  2017-01-13       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.